Latest news

• Roche, Novartis and Bayer gain NICE recommendations

  The second recommendation was for visual impairment due to macular oedema, secondary to central retinal vein occlusion (CRVO), which came in February last year.

• Bayer's Eylea cleared for wider use in Europe

  Previously, the label for the drug was limited to macular oedema secondary to central retinal vein occlusion (CRVO) in adults. ... BRVO is a common cause of visual impairment in the elderly and is around three times more common than CRVO, affected some

• Germany's IQWiG delivers bad news for Bayer’s Eylea

  If not, then a baseline price is set. IQWiG has already reviewed Eylea for two other indications - macular oedema following central retinal vein occlusion (CRVO) and wet age-related macular degeneration

• Eylea's UK launch earns Bayer PMEA success

  secondary to central retinal vein occlusion (CRVO).

• Bayer files eye drug Eylea for new use in EU

  The drug has already been approved for use in wet age-related macular degeneration (AMD) and macular oedema secondary to central retinal vein occlusion (CRVO). ... BRVO is around three times more common than CRVO so could provide a further fillip to